Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$28.05−0.41 (-1.44%)
Close on Nov 19, 2026Market cap $4.48BP/E –Yield –
Adaptive Biotechnologies shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Adaptive Biotechnologies's shares outstanding was 160M at Jun 30, 2026. For fiscal 2025 it was 152M, up 3.1% from the year before. The highest annual figure on record is 152M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 152M | +3.1% |
| FY2024 | Dec 31, 2024 | 147M | +1.9% |
| FY2023 | Dec 31, 2023 | 144M | +1.3% |
| FY2022 | Dec 31, 2022 | 143M | +1.5% |
| FY2021 | Dec 31, 2021 | 140M | +7.0% |
| FY2020 | Dec 31, 2020 | 131M | +89.7% |
| FY2019 | Dec 31, 2019 | 69M | +447.6% |
| FY2018 | Dec 31, 2018 | 13M | +3.5% |
| FY2017 | Dec 31, 2017 | 12M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 160M | +5.1% |
| Q1 FY2026 | Mar 31, 2026 | 156M | +4.2% |
| Q4 FY2025 | Dec 31, 2025 | 153M | +3.7% |
| Q3 FY2025 | Sep 30, 2025 | 163M | +10.6% |
| Q2 FY2025 | Jun 30, 2025 | 152M | +3.2% |
| Q1 FY2025 | Mar 31, 2025 | 149M | +2.3% |
| Q4 FY2024 | Dec 31, 2024 | 148M | +1.9% |
| Q3 FY2024 | Sep 30, 2024 | 148M | +1.9% |
| Q2 FY2024 | Jun 30, 2024 | 147M | +2.1% |
| Q1 FY2024 | Mar 31, 2024 | 146M | +1.6% |
| Q4 FY2023 | Dec 31, 2023 | 145M | +1.3% |
| Q3 FY2023 | Sep 30, 2023 | 145M | +1.2% |
| Q2 FY2023 | Jun 30, 2023 | 144M | +1.4% |
| Q1 FY2023 | Mar 31, 2023 | 144M | +1.3% |
| Q4 FY2022 | Dec 31, 2022 | 143M | +1.3% |
| Q3 FY2022 | Sep 30, 2022 | 143M | +1.5% |
| Q2 FY2022 | Jun 30, 2022 | 142M | +1.4% |
| Q1 FY2022 | Mar 31, 2022 | 142M | +2.0% |
| Q4 FY2021 | Dec 31, 2021 | 141M | +3.1% |
| Q3 FY2021 | Sep 30, 2021 | 141M | +4.8% |
| Q2 FY2021 | Jun 30, 2021 | 140M | +10.2% |
| Q1 FY2021 | Mar 31, 2021 | 139M | +10.2% |
| Q4 FY2020 | Dec 31, 2020 | 137M | +9.6% |
| Q3 FY2020 | Sep 30, 2020 | 134M | +8.1% |
| Q2 FY2020 | Jun 30, 2020 | 127M | +859.3% |
| Q1 FY2020 | Mar 31, 2020 | 126M | +878.3% |
| Q4 FY2019 | Dec 31, 2019 | 125M | +845.0% |
| Q3 FY2019 | Sep 30, 2019 | 124M | +884.8% |
| Q2 FY2019 | Jun 30, 2019 | 13M | +7.2% |
| Q1 FY2019 | Mar 31, 2019 | 13M | – |
| Q4 FY2018 | Dec 31, 2018 | 13M | – |
| Q3 FY2018 | Sep 30, 2018 | 13M | – |
| Q2 FY2018 | Jun 30, 2018 | 12M | – |
See a number that looks wrong?